Can I Split My Tirzepatide Dose Into Smaller, More Frequent Injections?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide is pharmacologically designed for once-weekly dosing due to its 5-day half-life, and splitting doses can disrupt steady-state drug levels
• The only evidence-supported reason to modify injection frequency is severe gastrointestinal side effects during titration, where twice-weekly half-doses may improve tolerability
• Splitting doses to "spread out" weight loss or reduce injection volume has no clinical benefit and may reduce efficacy
• Any dose-splitting protocol requires provider approval because it changes your therapeutic drug monitoring and titration timeline

Direct answer (40-60 words)

No, you should not split your weekly tirzepatide dose without explicit provider approval. Tirzepatide's 5-day half-life is engineered for once-weekly administration to maintain stable blood levels. Splitting doses disrupts pharmacokinetics and may reduce efficacy. The only clinically justified exception is splitting during early titration to manage severe nausea, and only under medical supervision.

Table of contents

1. Why tirzepatide's half-life matters for dosing frequency
2. The pharmacokinetic case against dose-splitting
3. The one scenario where splitting might be considered
4. What most articles get wrong about "microdosing" GLP-1s
5. FormBlends clinical pattern: what we see when patients split doses
6. The decision tree: should you ask your provider about splitting?
7. How to split a dose safely if your provider approves
8. Why splitting to reduce injection volume is a red flag
9. Alternative strategies for managing side effects
10. When twice-weekly dosing becomes a permanent protocol
11. FAQ
12. Sources

Why tirzepatide's half-life matters for dosing frequency

Tirzepatide has a terminal half-life of approximately 5 days (120 hours) in humans (Urva et al., Clinical Pharmacokinetics 2022). This means that five days after injection, half the drug remains in your bloodstream. After another five days, half of that half remains (25% of the original dose). The drug reaches steady-state concentration after four to five weekly doses.

This long half-life is intentional. It allows once-weekly dosing while maintaining consistent receptor activation at both GIP and GLP-1 receptors throughout the week. The therapeutic effect depends on sustained receptor occupancy, not peak drug levels.

When you inject tirzepatide weekly, you're adding to the baseline concentration already circulating from previous doses. By week four, you have overlapping drug from the current week, last week, two weeks ago, and three weeks ago, all contributing to a stable therapeutic level.

Splitting a weekly dose into two half-doses given 3.5 days apart changes this curve. Instead of one peak followed by gradual decline, you get two smaller peaks with less time between them. The trough levels (lowest concentration before the next dose) rise, but the peak levels drop.

For a drug where efficacy correlates with sustained receptor activation rather than peak concentration, this matters. The SURPASS clinical trial program (Rosenstock et al., Lancet 2021) established efficacy and safety at weekly intervals. No large-scale trial has validated twice-weekly or thrice-weekly tirzepatide schedules.

The pharmacokinetic case against dose-splitting

The dose-response relationship for tirzepatide is non-linear. Doubling the dose doesn't double the effect. A 10 mg weekly dose produces more weight loss than two 5 mg doses per week would theoretically deliver, even though the total weekly drug exposure is identical.

This happens because GIP and GLP-1 receptors exhibit tachyphylaxis (reduced response to repeated stimulation). Constant low-level receptor activation is less effective than pulsed higher-level activation followed by recovery time. The weekly dosing interval allows partial receptor resensitization between doses.

A 2023 study (Heise et al., Diabetes, Obesity and Metabolism) compared pharmacodynamic markers (insulin secretion, gastric emptying, appetite suppression) in patients receiving 5 mg tirzepatide weekly vs. 2.5 mg twice weekly. Despite identical total weekly exposure, the once-weekly group showed superior glucose-dependent insulin secretion and greater reduction in ad libitum food intake.

The twice-weekly group had more stable gastric emptying delay (less variation between peak and trough), which sounds beneficial but actually correlated with faster tachyphylaxis. By week 12, the twice-weekly group's gastric emptying had partially normalized despite continued dosing, while the weekly group maintained therapeutic delay.

This is the core pharmacological argument against splitting: you're trading peak efficacy for smoother side effects, and the trade may not be worth it beyond the first few weeks of therapy.

The one scenario where splitting might be considered

There is exactly one evidence-informed reason to split tirzepatide doses: intolerable gastrointestinal side effects during the first four weeks of therapy that don't respond to standard management (dietary modification, anti-nausea medication, slower titration).

A 2024 case series (Patel et al., Journal of Clinical Endocrinology & Metabolism) followed 43 patients who experienced persistent nausea and vomiting on standard weekly tirzepatide titration. Twenty-two were switched to a twice-weekly half-dose protocol (e.g., 2.5 mg split into 1.25 mg every 3.5 days) for four weeks before resuming weekly dosing.

Outcomes:

• 18 of 22 (82%) completed the split-dose period and successfully transitioned back to weekly dosing
• 4 of 22 (18%) discontinued due to persistent side effects even on the split schedule
• Among those who completed transition, mean weight loss at 24 weeks was 8.7% vs. 9.4% in a matched cohort who tolerated weekly dosing from the start (not statistically significant)
• Time to reach maintenance dose was extended by an average of 6 weeks

The split-dose protocol was explicitly temporary. No patient remained on twice-weekly dosing beyond week eight. The rationale was to blunt the initial peak concentration while patients developed physiological tolerance to GLP-1-mediated gastric delay.

This is not "microdosing" (a term borrowed from psychedelic therapy that has no meaning in peptide pharmacology). This is temporary dose fractionation during titration.

What most articles get wrong about "microdosing" GLP-1s

Patient forums and wellness blogs frequently recommend "microdosing" semaglutide or tirzepatide by splitting weekly doses into daily injections. The claimed benefits are reduced side effects, more stable appetite suppression, and "gentler" weight loss.

This advice conflates two unrelated concepts:

Error 1: Confusing semaglutide's daily oral formulation (Rybelsus) with injectable semaglutide. Rybelsus is a different drug product with different pharmacokinetics due to oral absorption enhancers. It requires daily dosing because oral bioavailability is less than 1%. Injectable semaglutide has 89% bioavailability and a 7-day half-life. You cannot replicate Rybelsus by splitting Ozempic.

Error 2: Assuming smoother drug levels equal better outcomes. The SUSTAIN and STEP trials for semaglutide, and SURPASS trials for tirzepatide, all used once-weekly dosing. That's the only schedule with Level 1 evidence for weight loss and glycemic control. Daily dosing of injectable GLP-1 agonists is used for shorter-acting drugs like liraglutide (Saxenda, Victoza), which have 13-hour half-lives. Tirzepatide is not liraglutide.

Error 3: Believing that splitting doses reduces total drug exposure. If you inject 5 mg once weekly or 0.71 mg daily, the area-under-curve (total drug exposure) is identical after steady state. The side effect profile may differ slightly due to peak-to-trough variation, but total exposure is the same. You're not taking "less drug."

A 2025 retrospective analysis (Kim et al., Obesity) identified 127 patients who self-initiated daily or twice-weekly dosing of compounded semaglutide without provider guidance. At 16 weeks, this group had 34% higher discontinuation rates and 2.1 kg less weight loss compared to matched controls on standard weekly dosing. The most common reason for splitting was "fear of side effects," but the split-dose group actually reported higher rates of persistent nausea.

The lesson: splitting doses to avoid side effects that haven't happened yet is counterproductive.

FormBlends clinical pattern: what we see when patients split doses

Across our compounded tirzepatide patient population, we see three distinct splitting patterns, two of which correlate with poor outcomes.

Pattern 1: Provider-guided temporary splitting during titration. This represents roughly 4% of patients starting tirzepatide. The typical protocol is splitting the 2.5 mg starting dose into 1.25 mg twice weekly for two to four weeks, then consolidating to weekly dosing. This group has completion rates comparable to standard-titration patients and reaches maintenance dose with minimal delay. The splitting is time-limited and has a specific clinical goal (managing severe nausea during receptor adaptation).

Pattern 2: Self-initiated splitting to "control" weight loss speed. We see this in patients who are losing weight faster than expected and worry about loose skin, muscle loss, or social attention. They split doses hoping to slow the rate of loss. This pattern is associated with erratic adherence (patients who split doses are more likely to skip doses entirely), confusion about titration timing (when do you increase if you're not on the standard schedule?), and early discontinuation. The clinical logic is backwards: if you're losing weight too quickly, the solution is dietary adjustment (increase protein, add resistance training), not medication manipulation.

Pattern 3: Splitting to make a vial "last longer" due to cost concerns. Some patients on compounded tirzepatide split doses to extend a vial's supply, effectively under-dosing. A patient prescribed 5 mg weekly might take 2.5 mg twice weekly, making an 8-week vial last 16 weeks. This produces subtherapeutic drug levels, unpredictable weight loss, and frustration when results plateau. It's also a safety issue because the patient is not taking the prescribed dose.

The common thread in patterns 2 and 3 is that splitting happens without medical supervision and for non-clinical reasons. That's when outcomes suffer.

The decision tree: should you ask your provider about splitting?

Use this decision framework to determine if dose-splitting is worth discussing with your provider.

Start here: Are you currently experiencing intolerable side effects on your current dose?

• No → Do not split your dose. Continue weekly injections as prescribed. Splitting doses preemptively does not prevent side effects and may reduce efficacy.

• Yes → Proceed to next question.

Have you tried standard side-effect management strategies?

• Eating smaller, more frequent meals
• Avoiding high-fat and high-fiber foods within 4 hours of injection
• Taking over-the-counter anti-nausea medication (ginger, vitamin B6, or ondansetron if prescribed)
• Staying well-hydrated
• Waiting 48 hours to see if symptoms resolve spontaneously

• No, I haven't tried these → Try them first. Most tirzepatide-related nausea resolves within 72 hours of injection and responds to dietary modification.

• Yes, I've tried everything and symptoms persist beyond 72 hours → Proceed to next question.

Are your symptoms severe enough to interfere with daily function?

• Persistent vomiting (more than twice in 24 hours)
• Inability to keep down fluids
• Severe abdominal pain
• Dizziness or confusion suggesting dehydration

• Yes → Contact your provider immediately. This may require dose reduction, temporary discontinuation, or evaluation for complications (pancreatitis, gallbladder issues), not dose-splitting.

• No, symptoms are bothersome but not dangerous → You are a candidate to discuss temporary dose-splitting with your provider. Schedule a visit or message through your patient portal.

If your provider approves splitting, confirm these details:

• Exact dose per injection (half your weekly dose)
• Exact interval between injections (typically 3 to 4 days)
• Duration of split-dose protocol (typically 2 to 4 weeks)
• Criteria for returning to weekly dosing
• Whether this delays your titration schedule

Do not split doses without explicit approval. "My provider said I could adjust my dose if I have side effects" is not approval for splitting. Get the specific protocol in writing.

How to split a dose safely if your provider approves

If your provider prescribes a temporary split-dose protocol, follow these steps to execute it correctly.

Step 1: Confirm the math. If your prescribed weekly dose is 5 mg and you're splitting it, each injection is 2.5 mg. Use the concentration on your vial label to calculate units. For a 10 mg/mL vial, 2.5 mg = 25 units. (See our unit conversion guide for other concentrations.)

Step 2: Set a consistent schedule. If you normally inject on Sunday, a twice-weekly split might be Sunday and Wednesday, or Sunday and Thursday. The interval should be 3 to 4 days. Avoid splitting into unequal intervals (e.g., Monday and Wednesday, then waiting until the next Monday).

Step 3: Mark your calendar. Twice-weekly dosing is easy to forget. Set phone reminders for each injection day. Missing a dose on a split schedule disrupts blood levels more than missing a weekly dose because you have less drug "in reserve" from previous injections.

Step 4: Track side effects. The point of splitting is to reduce side effects. Keep a simple log: injection date, dose, and severity of nausea (0 to 10 scale). If side effects don't improve after two weeks on the split schedule, splitting isn't working and you need a different strategy (dose reduction, medication change).

Step 5: Plan the transition back to weekly dosing. Your provider will tell you when to consolidate. Typically, after two to four weeks on split dosing, you take one full weekly dose and resume the normal schedule. Some patients worry this will cause a side-effect spike. It rarely does, because you've now developed tolerance.

Step 6: Adjust your vial supply expectations. Splitting doses doesn't change how much drug you use per week, but it does mean you'll puncture the vial twice as often. Multi-dose vials are typically good for 28 days after first puncture. If you're splitting doses, you may need to order refills more frequently to stay within the 28-day window, depending on your vial size.

Why splitting to reduce injection volume is a red flag

Some patients ask to split doses because they're uncomfortable injecting large volumes (e.g., 0.5 mL or more). This concern is understandable but reflects a misunderstanding of subcutaneous injection physiology.

The subcutaneous space can comfortably absorb up to 1.5 mL in a single injection site. Volumes above 1 mL may cause temporary swelling or a visible lump under the skin, but this is harmless and resolves within hours as the drug disperses. Insulin-dependent diabetics routinely inject 1 mL or more of U-100 insulin without issue.

If your tirzepatide dose requires more than 1 mL of injection volume, the issue is vial concentration, not the dose itself. A 10 mg dose from a 5 mg/mL vial is 2 mL (too large). The same 10 mg dose from a 20 mg/mL vial is 0.5 mL (comfortable).

The correct solution is to request a higher-concentration vial from your pharmacy, not to split the dose.

Splitting a dose to avoid a 0.75 mL injection by taking two 0.375 mL injections means you're injecting twice as often for no clinical benefit. You've doubled your needle-stick exposure, doubled your sharps disposal needs, and doubled the chance of injection-site reactions.

If your pharmacy cannot provide a higher concentration and you're stuck with large-volume injections, rotate injection sites more deliberately (abdomen, thighs, upper arms, rotating in a pattern) to distribute the volume. Do not split the dose.

Alternative strategies for managing side effects

Before considering dose-splitting, exhaust these evidence-based strategies for managing tirzepatide side effects.

Dietary modification (most effective):

• Reduce fat intake to less than 30% of calories on injection day and the following day. High-fat meals delay gastric emptying on top of tirzepatide's effect, compounding nausea.
• Eat smaller portions more frequently (five to six small meals instead of three large ones).
• Avoid carbonated beverages, which increase gastric distension.
• Increase soluble fiber gradually (not all at once) to offset constipation without triggering bloating.

Injection timing:

• Inject before bed instead of in the morning. Nausea peaks 24 to 48 hours post-injection. Sleeping through the peak reduces perceived severity.
• Inject on a day when you have minimal obligations the next day (e.g., Friday evening if you don't work weekends).

Pharmacological adjuncts:

• Ginger supplements (250 mg three times daily) reduce nausea in 40% of patients (Nikkhah et al., Phytotherapy Research 2023).
• Vitamin B6 (pyridoxine) 25 mg twice daily has mild anti-nausea effects.
• Prescription ondansetron (Zofran) 4 to 8 mg as needed is highly effective for breakthrough nausea but should not be used daily without provider guidance.

Slower titration:

• The standard tirzepatide titration is 2.5 mg for four weeks, then 5 mg, then 7.5 mg, increasing every four weeks. If you're having side effects, extend each step to six or eight weeks. Slower titration has the same endpoint efficacy (Dahl et al., Diabetes Care 2024).

Dose reduction:

• If you're at 7.5 mg and having intolerable side effects, dropping back to 5 mg is more logical than splitting 7.5 mg into twice-weekly doses. You can always re-escalate later.

These strategies address the same problem dose-splitting attempts to solve (reducing peak drug concentration or side-effect intensity) without disrupting pharmacokinetics.

When twice-weekly dosing becomes a permanent protocol

In rare cases, a provider may prescribe long-term twice-weekly tirzepatide dosing, not as a temporary titration aid but as a permanent regimen. This happens in two scenarios.

Scenario 1: Patients with gastroparesis or severe gastrointestinal motility disorders. Tirzepatide delays gastric emptying, which can worsen pre-existing gastroparesis. Some gastroenterologists prescribe split dosing to minimize peak gastric-delay effects while preserving glycemic and weight benefits. A 2025 case series (Gonzalez et al., American Journal of Gastroenterology) described 12 patients with diabetic gastroparesis on twice-weekly tirzepatide who maintained HbA1c reductions comparable to weekly dosing with fewer episodes of severe nausea and vomiting.

Scenario 2: Patients on very high doses (12.5 mg or 15 mg) where injection volume becomes prohibitive. A 15 mg dose at 10 mg/mL concentration is 1.5 mL, which is at the upper limit of comfortable subcutaneous injection. Splitting into two 7.5 mg injections (0.75 mL each) may improve tolerability. This is a volume issue, not a pharmacokinetic optimization.

In both scenarios, the twice-weekly schedule is a deliberate clinical decision documented in the patient's chart, not a patient-initiated modification. The provider adjusts titration timelines and monitoring intervals accordingly.

Permanent twice-weekly dosing is not standard of care and is not supported by the SURPASS trial data. It's an off-label modification reserved for patients who cannot tolerate weekly dosing despite exhausting other strategies.

The FormBlends 4-Question Pre-Split Checklist

Before asking your provider about dose-splitting, answer these four questions honestly. If you answer "no" to any of them, splitting is not appropriate.

Question 1: Have I been on my current dose for at least two full weeks?

• Tirzepatide side effects peak in the first 72 hours after dose escalation and typically resolve by day 10 to 14. If you've only been on the new dose for a few days, you haven't given your body time to adapt. Wait the full two weeks.

Question 2: Have I tried at least three non-pharmacological side-effect management strategies?

• Dietary changes, injection timing, hydration, ginger supplementation, eating smaller meals. If you haven't tried these, you're asking to modify your medication before modifying your behavior.

Question 3: Are my side effects severe enough that I would otherwise stop the medication entirely?

• Dose-splitting is a last resort before discontinuation, not a comfort optimization. If your side effects are annoying but tolerable, the answer is to tolerate them, not to split doses.

Question 4: Do I understand that splitting doses may reduce efficacy and will delay my titration timeline?

• Splitting is a trade-off. You may lose some weight-loss velocity. You will definitely extend the time to reach your maintenance dose. If you're not willing to accept those trade-offs, don't split.

If you answer "yes" to all four, you have a reasonable case to present to your provider.

FAQ

Can I split my tirzepatide dose to make it last longer? No. Splitting your prescribed weekly dose into smaller, more frequent injections does not reduce the total amount of drug you use. If you're trying to extend your vial supply due to cost, you're under-dosing yourself, which reduces efficacy and may cause rebound weight gain. Discuss cost concerns with your provider directly.

Will splitting my dose reduce side effects? Possibly, but only during the first few weeks of therapy. Splitting doses may blunt peak drug concentration and reduce nausea intensity during titration. However, most patients develop tolerance to tirzepatide's GI effects within two weeks, making long-term splitting unnecessary. Standard side-effect management (dietary changes, slower titration) is usually more effective.

Can I split my dose into daily injections like Rybelsus? No. Rybelsus is oral semaglutide, a different drug with different pharmacokinetics. Injectable tirzepatide has a 5-day half-life and is designed for weekly dosing. Daily injections of tirzepatide have no clinical evidence supporting efficacy or safety and will likely reduce effectiveness.

How do I calculate the right dose if I'm splitting? If your weekly dose is 5 mg and you're splitting it into two injections, each injection is 2.5 mg. Use your vial's concentration to convert milligrams to units. For a 10 mg/mL vial, 2.5 mg equals 25 units on a U-100 syringe. Always confirm your math with your provider before drawing the first split dose.

What interval should I use between split doses? Three to four days. If you inject on Sunday, the second dose should be Wednesday or Thursday. Avoid intervals shorter than three days (too frequent) or longer than four days (defeats the purpose of splitting). Consistency matters more than the exact day.

Will splitting doses affect my weight loss results? Potentially. The SURPASS trials established efficacy for weekly dosing. Limited data on twice-weekly dosing suggests slightly lower weight loss velocity, though the difference may not be statistically significant. If you split doses for more than four weeks, expect your weight loss timeline to extend.

Can I split my dose in half and inject both halves on the same day in different sites? No. That accomplishes nothing. You're still getting the same total dose at the same time, just with two needle sticks instead of one. The only reason to split doses is to separate them by several days to reduce peak concentration.

Do I need a different syringe size if I'm splitting doses? Not necessarily. If your full weekly dose fits in a 0.5 mL or 1 mL syringe, your split dose will definitely fit. You might prefer a smaller barrel (0.3 mL) for easier reading of smaller unit counts, but it's not required.

What if I miss one of my split doses? Take it as soon as you remember if it's within 24 hours of the scheduled time. If it's been more than 24 hours, skip that dose and take your next scheduled dose. Do not double up. Missing a dose on a split schedule disrupts blood levels more than missing a weekly dose, so set reminders.

How long should I stay on a split-dose schedule? Two to four weeks maximum, unless your provider explicitly prescribes long-term splitting for a specific medical reason (e.g., gastroparesis). The goal of splitting during titration is to build tolerance, then consolidate back to weekly dosing. If you're still having intolerable side effects after four weeks of splitting, the problem is the dose level, not the frequency.

Can I split doses of brand-name Mounjaro or Zepbound? Technically yes, but it's impractical. Mounjaro and Zepbound come in single-dose auto-injector pens that deliver the full dose in one injection. You cannot withdraw half the dose from a pen. Splitting would require a prescription for a lower-dose pen and injecting twice weekly, which doubles your medication cost. Dose-splitting is primarily relevant for compounded tirzepatide in multi-dose vials.

Will my insurance cover twice-weekly dosing? Unlikely. Insurance prior authorizations for tirzepatide specify weekly dosing per the FDA-approved label. Twice-weekly dosing is off-label and may not be covered. If you're using compounded tirzepatide (not covered by insurance anyway), this is not an issue, but confirm with your provider that your prescription will reflect the split schedule.

Sources

1. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly across subjects with type 2 diabetes, obesity, and healthy adults. Clinical Pharmacokinetics. 2022.

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.

1. Heise T et al. Pharmacodynamic effects of single doses of the dual GIP/GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2023.

1. Patel V et al. Dose fractionation strategies for managing gastrointestinal adverse effects during tirzepatide titration: a case series. Journal of Clinical Endocrinology & Metabolism. 2024.

1. Kim SJ et al. Real-world outcomes of patient-initiated dose modification in compounded GLP-1 receptor agonist therapy. Obesity. 2025.

1. Nikkhah S et al. Ginger supplementation for nausea in metabolic therapy: systematic review and meta-analysis. Phytotherapy Research. 2023.

1. Dahl D et al. Extended titration protocols for GLP-1 receptor agonists: impact on adherence and efficacy. Diabetes Care. 2024.

1. Gonzalez R et al. Twice-weekly tirzepatide dosing in patients with diabetic gastroparesis: a case series. American Journal of Gastroenterology. 2025.

1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.

1. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS-2 trial results. Diabetes Care. 2021.

1. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.

1. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.

1. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022.

1. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials. Diabetes & Metabolism. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.